Refractory mucosal candidiasis in advanced human immunodeficiency virus infection

C. J. Fichtenbaum, S. Koletar, Constantin Yiannoutsos, F. Holland, J. Pottage, S. E. Cohn, A. Walawander, P. Frame, J. Feinberg, M. Saag, C. Van der Horst, W. G. Powderly

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

We conducted a multicenter, prospective study of the risk factors, natural history, and outcome of fluconazole-refractory mucosal candidiasis (FRMC) in 832 persons with advanced human immunodeficiency virus (HIV) infection (median CD4 cell count, 14/mm3) during 1994-1996. FRMC was defined as mucosal candidiasis that failed to resolve despite 14 days of therapy with daily doses (≥200 mg) of fluconazole. Thirty-six persons (4.3%) had FRMC (35, oral; 1, esophageal), for an incidence of 4.2 per 100 person-years (859.7 total years of follow-up). In a multivariate model, the use of trimethoprim-sulfamethoxazole within 6 months of enrollment (relative risk [RR], 2.39; P = .04) and the use of fluconazole daily or every other day (RR, 5.64; P = .004) were significantly associated with the development of FRMC. The median survival after the development of FRMC was 32.6 weeks. In conclusion, the annual incidence of FRMC was

Original languageEnglish (US)
Pages (from-to)749-756
Number of pages8
JournalClinical Infectious Diseases
Volume30
Issue number5
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Fluconazole
Candidiasis
Virus Diseases
HIV
Oral Candidiasis
Incidence
Sulfamethoxazole Drug Combination Trimethoprim
CD4 Lymphocyte Count
Natural History
Multicenter Studies
Prospective Studies
Survival

ASJC Scopus subject areas

  • Immunology

Cite this

Fichtenbaum, C. J., Koletar, S., Yiannoutsos, C., Holland, F., Pottage, J., Cohn, S. E., ... Powderly, W. G. (2000). Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. Clinical Infectious Diseases, 30(5), 749-756. https://doi.org/10.1086/313765

Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. / Fichtenbaum, C. J.; Koletar, S.; Yiannoutsos, Constantin; Holland, F.; Pottage, J.; Cohn, S. E.; Walawander, A.; Frame, P.; Feinberg, J.; Saag, M.; Van der Horst, C.; Powderly, W. G.

In: Clinical Infectious Diseases, Vol. 30, No. 5, 2000, p. 749-756.

Research output: Contribution to journalArticle

Fichtenbaum, CJ, Koletar, S, Yiannoutsos, C, Holland, F, Pottage, J, Cohn, SE, Walawander, A, Frame, P, Feinberg, J, Saag, M, Van der Horst, C & Powderly, WG 2000, 'Refractory mucosal candidiasis in advanced human immunodeficiency virus infection', Clinical Infectious Diseases, vol. 30, no. 5, pp. 749-756. https://doi.org/10.1086/313765
Fichtenbaum, C. J. ; Koletar, S. ; Yiannoutsos, Constantin ; Holland, F. ; Pottage, J. ; Cohn, S. E. ; Walawander, A. ; Frame, P. ; Feinberg, J. ; Saag, M. ; Van der Horst, C. ; Powderly, W. G. / Refractory mucosal candidiasis in advanced human immunodeficiency virus infection. In: Clinical Infectious Diseases. 2000 ; Vol. 30, No. 5. pp. 749-756.
@article{30b2744e522b4610b26c3f92012f7dc4,
title = "Refractory mucosal candidiasis in advanced human immunodeficiency virus infection",
abstract = "We conducted a multicenter, prospective study of the risk factors, natural history, and outcome of fluconazole-refractory mucosal candidiasis (FRMC) in 832 persons with advanced human immunodeficiency virus (HIV) infection (median CD4 cell count, 14/mm3) during 1994-1996. FRMC was defined as mucosal candidiasis that failed to resolve despite 14 days of therapy with daily doses (≥200 mg) of fluconazole. Thirty-six persons (4.3{\%}) had FRMC (35, oral; 1, esophageal), for an incidence of 4.2 per 100 person-years (859.7 total years of follow-up). In a multivariate model, the use of trimethoprim-sulfamethoxazole within 6 months of enrollment (relative risk [RR], 2.39; P = .04) and the use of fluconazole daily or every other day (RR, 5.64; P = .004) were significantly associated with the development of FRMC. The median survival after the development of FRMC was 32.6 weeks. In conclusion, the annual incidence of FRMC was",
author = "Fichtenbaum, {C. J.} and S. Koletar and Constantin Yiannoutsos and F. Holland and J. Pottage and Cohn, {S. E.} and A. Walawander and P. Frame and J. Feinberg and M. Saag and {Van der Horst}, C. and Powderly, {W. G.}",
year = "2000",
doi = "10.1086/313765",
language = "English (US)",
volume = "30",
pages = "749--756",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Refractory mucosal candidiasis in advanced human immunodeficiency virus infection

AU - Fichtenbaum, C. J.

AU - Koletar, S.

AU - Yiannoutsos, Constantin

AU - Holland, F.

AU - Pottage, J.

AU - Cohn, S. E.

AU - Walawander, A.

AU - Frame, P.

AU - Feinberg, J.

AU - Saag, M.

AU - Van der Horst, C.

AU - Powderly, W. G.

PY - 2000

Y1 - 2000

N2 - We conducted a multicenter, prospective study of the risk factors, natural history, and outcome of fluconazole-refractory mucosal candidiasis (FRMC) in 832 persons with advanced human immunodeficiency virus (HIV) infection (median CD4 cell count, 14/mm3) during 1994-1996. FRMC was defined as mucosal candidiasis that failed to resolve despite 14 days of therapy with daily doses (≥200 mg) of fluconazole. Thirty-six persons (4.3%) had FRMC (35, oral; 1, esophageal), for an incidence of 4.2 per 100 person-years (859.7 total years of follow-up). In a multivariate model, the use of trimethoprim-sulfamethoxazole within 6 months of enrollment (relative risk [RR], 2.39; P = .04) and the use of fluconazole daily or every other day (RR, 5.64; P = .004) were significantly associated with the development of FRMC. The median survival after the development of FRMC was 32.6 weeks. In conclusion, the annual incidence of FRMC was

AB - We conducted a multicenter, prospective study of the risk factors, natural history, and outcome of fluconazole-refractory mucosal candidiasis (FRMC) in 832 persons with advanced human immunodeficiency virus (HIV) infection (median CD4 cell count, 14/mm3) during 1994-1996. FRMC was defined as mucosal candidiasis that failed to resolve despite 14 days of therapy with daily doses (≥200 mg) of fluconazole. Thirty-six persons (4.3%) had FRMC (35, oral; 1, esophageal), for an incidence of 4.2 per 100 person-years (859.7 total years of follow-up). In a multivariate model, the use of trimethoprim-sulfamethoxazole within 6 months of enrollment (relative risk [RR], 2.39; P = .04) and the use of fluconazole daily or every other day (RR, 5.64; P = .004) were significantly associated with the development of FRMC. The median survival after the development of FRMC was 32.6 weeks. In conclusion, the annual incidence of FRMC was

UR - http://www.scopus.com/inward/record.url?scp=0033807041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033807041&partnerID=8YFLogxK

U2 - 10.1086/313765

DO - 10.1086/313765

M3 - Article

VL - 30

SP - 749

EP - 756

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 5

ER -